RELAPSED ADULT AML
Clinical trials for RELAPSED ADULT AML explained in plain language.
Never miss a new study
Get alerted when new RELAPSED ADULT AML trials appear
Sign up with your email to follow new studies for RELAPSED ADULT AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough leukemia: Triple-Drug combo shows promise
Disease control Recruiting nowThis study tests a combination of three drugs (venetoclax, chidamide, and azacitidine) in adults whose acute myeloid leukemia has returned or not responded to prior treatment. The goal is to see if this mix can safely achieve remission. About 30 participants will receive the trea…
Matched conditions: RELAPSED ADULT AML
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated Jun 22, 2026 12:05 UTC
-
Engineered immune cells offer new hope for Hard-to-Treat leukemia
Disease control Recruiting nowThis early-phase study tests whether specially engineered immune cells (CAR-T cells) that target a protein called CD19 are safe for adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. Only patients whose leukemia cells show high levels of CD…
Matched conditions: RELAPSED ADULT AML
Phase: PHASE1 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 22, 2026 12:02 UTC
-
Engineered immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-stage trial is testing a new treatment made from a person's own immune cells, called CLL-1 CAR-NK cells, for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The study aims to see if the treatment is safe and tolerable, …
Matched conditions: RELAPSED ADULT AML
Phase: PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
Immune cell 'Bridge' offers new hope for tough leukemia
Disease control Recruiting nowThis study tests a new immune cell treatment called AdaptNK for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses specially selected natural killer cells from a donor, given after chemotherapy, to help control the…
Matched conditions: RELAPSED ADULT AML
Phase: PHASE1, PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC